List of Excipients in Branded Drug BARACLUDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	CELLULOSE, MICROCRYSTALLINE
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	CROSPOVIDONE
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	HYPROMELLOSE
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	LACTOSE MONOHYDRATE
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	MAGNESIUM STEARATE
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	POLYETHYLENE GLYCOL 400
ER Squibb & Sons LLC	BARACLUDE	entecavir	0003-1611	POLYSORBATE 80

BARACLUDE Excipient Strategy and Commercial Opportunities for Entecavir

Last updated: August 17, 2026

Baraclude is entecavir, an oral nucleoside analogue used to treat chronic hepatitis B virus infection. Its commercial opportunity has shifted from originator exclusivity to generic manufacturing, pediatric delivery, excipient substitution, and differentiated oral dosage forms. The core tablet is a low-dose immediate-release product with a relatively simple excipient system. The most credible opportunities are lactose-free tablets, improved pediatric liquids, preservative-reduced formulations, orally disintegrating tablets, and cost-optimized generic production.

What is Baraclude and which dosage forms are commercially relevant?

Baraclude contains entecavir and is marketed primarily as 0.5 mg and 1 mg film-coated tablets, with an oral solution concentration of 0.05 mg/mL. The product is used in adults and pediatric patients at least 2 years of age who have chronic hepatitis B and meet the labeled treatment criteria.[1]

Product attribute	Baraclude specification
Active ingredient	Entecavir
Therapeutic class	Hepatitis B antiviral
Main dosage forms	Film-coated tablets; oral solution
Tablet strengths	0.5 mg and 1 mg
Oral solution	0.05 mg/mL
Original sponsor	Bristol-Myers Squibb
U.S. approval	2005
Pediatric use	Patients at least 2 years old under labeled conditions
Generic pathway	Abbreviated New Drug Application, or ANDA
Biosimilar pathway	Not applicable because entecavir is a small molecule

The low entecavir dose creates a content-uniformity challenge. A 0.5 mg tablet contains a small quantity of active pharmaceutical ingredient relative to the total tablet mass. Blend homogeneity, segregation control, sampling strategy, and validated assay performance are therefore more important than the absolute drug load.

What excipients are used in Baraclude tablets?

The U.S. labeling identifies lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate in the tablet core. The film coating includes common coating polymers and colorants, including hypromellose, polyethylene glycol, and titanium dioxide. The exact colorant system differs by strength.[1]

Baraclude tablet excipient functions

Excipient	Primary function	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Potential barrier for lactose-intolerant patients and certain market-specific claims
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and manufacturability
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Povidone	Binder	Supports granulation and tablet strength
Magnesium stearate	Lubricant	Controls ejection force and tooling performance
Hypromellose	Film-forming polymer	Provides the tablet coating
Polyethylene glycol	Coating plasticizer	Improves coating flexibility
Titanium dioxide and colorants	Opacification and identification	Supports strength differentiation and appearance control

The formulation is conventional, which benefits generic manufacturers. Conventional excipients have established compendial grades, multiple suppliers, extensive toxicology histories, and broad regulatory precedent. The same simplicity limits the ability to obtain strong formulation patent protection unless a reformulation delivers a measurable benefit.

What excipients are used in Baraclude oral solution?

The oral solution uses maltitol, sodium citrate, citric acid, methylparaben, propylparaben, sucralose, and an orange flavor system, according to U.S. prescribing information.[1]

Oral-solution component	Likely formulation role
Maltitol	Sweetener and vehicle-solids contributor
Sodium citrate and citric acid	Buffering and pH control
Methylparaben and propylparaben	Preservation
Sucralose	High-intensity sweetener
Orange flavor	Taste masking and patient acceptability

The solution has greater excipient complexity than the tablets. Its commercial risks include preservative sensitivity, flavor variability, microbial control, viscosity changes, container-closure compatibility, and dose-measurement accuracy.

Maltitol can also create gastrointestinal tolerability considerations at sufficient exposure. A reformulated pediatric product could evaluate alternative polyols, non-caloric sweeteners, or a lower-excipient-dose system while maintaining acceptable taste and chemical stability.

What excipient strategy is best for generic entecavir tablets?

The lowest-risk generic strategy is a compositionally simple immediate-release tablet that maintains rapid disintegration, robust content uniformity, and bioequivalence to the reference product. Generic developers should avoid unnecessary excipient changes that create dissolution, impurity, or manufacturing variability.

Three platform strategies are commercially relevant:

Conventional direct compression

A direct-compression blend using microcrystalline cellulose, a superdisintegrant, a binder or dry binder, and magnesium stearate can reduce process steps and manufacturing cost. The main risk is poor blend uniformity because entecavir is present at a low dose.

This approach is most attractive where the active ingredient has suitable flow and the manufacturer has high-shear blending and segregation-control capability.

Dry granulation

Roller compaction can improve flow and reduce segregation. It may be useful when the active ingredient or excipient blend has poor flow characteristics. The process can, however, alter tabletability and dissolution. Excessive compaction can produce hard granules that slow disintegration.

Wet granulation

Wet granulation offers stronger control over blend uniformity and tablet mechanical properties. It introduces additional risks involving residual moisture, hydrolytic stability, drying endpoint control, and process cost. It is less attractive if the active ingredient or formulation has moisture sensitivity.

For all three approaches, the critical quality attributes are assay, content uniformity, dissolution, tablet hardness, friability, degradation products, and stability under humidity exposure. The formulation should be designed around the reference product’s dissolution profile and the ANDA’s bioequivalence requirements rather than around excipient novelty.

What formulation patents could protect differentiated entecavir products?

A standard generic tablet is difficult to protect with a strong, commercially durable patent because its excipient architecture is routine. More defensible formulation claims would need to cover a specific technical result, such as:

• Improved palatability in pediatric patients.
• A preservative-free or preservative-reduced oral liquid with validated microbial control.
• A stable liquid formulation with a defined pH and impurity profile.
• An orally disintegrating tablet with rapid disintegration and acceptable mouthfeel.
• A dispersible tablet or granule product for patients unable to swallow tablets.
• A moisture-protective package and formulation combination.
• A multiparticulate formulation that improves dose flexibility.
• A high-content-uniformity manufacturing process for low-dose entecavir.
• A formulation with reduced gastrointestinal effects associated with sweeteners or polyols.

A patent application would need comparative data showing a technical advantage. Merely replacing lactose with mannitol, changing one superdisintegrant, or substituting one flavor would generally provide a weaker inventive-position argument unless the change produces an unexpected stability, dissolution, tolerability, or manufacturability benefit.

When did Baraclude lose U.S. exclusivity?

Baraclude’s originator exclusivity has ended, and generic entecavir products are available in the U.S. The product therefore presents conventional generic competition rather than a near-term loss-of-exclusivity opportunity.

The relevant U.S. regulatory milestones are:

Event	Timing
FDA approval of Baraclude	2005
Generic entecavir development	Following expiry or loss of enforceable U.S. exclusivity
Generic market entry	Mid-2010s
Current commercial model	Originator brand plus generic competition, with price pressure

The exact launch rights of each generic depend on the applicant’s patents, certifications, litigation history, settlement terms, and FDA approval status. The Orange Book remains the controlling source for listed patents and regulatory exclusivity status.[2]

What is the Orange Book status of Baraclude?

Baraclude is an approved small-molecule product subject to the Hatch-Waxman framework. Generic applicants can file ANDAs with Paragraph III or Paragraph IV certifications against relevant listed patents.

A Paragraph IV filing alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The first qualifying Paragraph IV applicant may receive 180-day exclusivity under applicable statutory conditions. That opportunity is commercially important during the initial generic-entry period but is largely historical for entecavir because multiple generic products have already reached the market.

The primary current questions for a generic entrant are:

1. Which Baraclude patents remain listed in the Orange Book?
2. Are any listed patents still unexpired?
3. Does the proposed formulation practice a listed formulation claim?
4. Does the label create method-of-use exposure?
5. Has a 30-month stay been triggered by patent litigation?
6. Are pediatric or regulatory exclusivities still relevant?

Because entecavir is an established product with generic competition, the main patent risk is generally product-specific, formulation-specific, or manufacturing-specific rather than molecule-wide exclusivity.

Which companies are challenging Baraclude, and what litigation affects generic entry?

Multiple generic manufacturers have pursued entecavir tablets and oral solutions through ANDA filings. Publicly reported generic activity has included large and mid-sized generic companies, including Teva, Dr. Reddy’s Laboratories, Aurobindo, and other ANDA sponsors.

The commercial significance of historic Paragraph IV litigation has declined as generic entecavir has become established. Litigation risk remains relevant for a new differentiated product if it relies on a later-expiring formulation, process, or method-of-use patent.

A generic entrant should separate four risk categories:

Risk category	Relevance to entecavir
Active-ingredient patent	Low for established generic entry
Formulation patent	Material for novel liquids, ODTs, granules, or modified products
Method-of-use patent	Potentially relevant to label design and carve-outs
Manufacturing patent	Relevant if a specific process is required or claimed

Settlement agreements may affect the timing of individual generic launches. They do not necessarily prevent other ANDA sponsors from entering after the relevant patents expire or are successfully challenged. A reliable competitive assessment must review FDA approvals, Orange Book listings, court dockets, and any public settlement disclosures together.

Are biosimilars a risk for Baraclude?

No. Biosimilar competition does not apply to Baraclude because entecavir is a chemically synthesized small molecule, not a biologic. The applicable competitive products are generic entecavir tablets and oral solutions approved through the ANDA pathway.

This distinction matters commercially. Generic approval is primarily based on pharmaceutical equivalence and bioequivalence. A developer does not need to reproduce the originator’s complete excipient composition, but it must demonstrate that the proposed product meets applicable quality and bioequivalence requirements.

What pediatric excipient opportunities exist for entecavir?

Pediatric delivery is the strongest excipient-related opportunity because Baraclude already has pediatric use and an oral solution. The development target is not simply a cheaper liquid. It is a product that improves dosing accuracy, taste, storage, administration, or caregiver handling.

Potential pediatric product concepts

• Sugar-free or lower-calorie oral solution.
• Preservative-reduced liquid with a validated multidose container system.
• Unit-dose oral liquid sachets or stick packs.
• Dispersible granules for reconstitution.
• Mini-tablets for children who can swallow solid dosage forms.
• Orally disintegrating tablets for older pediatric patients.
• A more concentrated solution that reduces administration volume.
• Dosing devices with improved low-volume accuracy.

Any concentrated product must address dose-measurement error. A 0.05 mg/mL solution requires a 10 mL volume for a 0.5 mg dose. A higher concentration could reduce volume, but it would increase the consequence of measurement mistakes and require new stability and bioequivalence work.

Palatability is also a significant product attribute. Entecavir products can use flavor systems, sweeteners, buffers, and viscosity modifiers, but these excipients may alter chemical stability or microbial risk. A taste-masking strategy should be tested with the full formulation and the intended container-closure system.

What commercial opportunities exist beyond a conventional generic tablet?

The opportunity set is segmented by development cost and regulatory complexity.

Opportunity	Development burden	Commercial rationale
Standard 0.5 mg tablet	Low	Established demand and simple ANDA pathway
Standard 1 mg tablet	Low	Supports dose flexibility and existing reference strength
Lactose-free tablet	Low to moderate	Differentiation for excipient-sensitive patients and selected markets
Improved oral solution	Moderate	Pediatric adherence and caregiver convenience
Preservative-reduced liquid	Moderate to high	Potential tolerability and label differentiation
ODT or dispersible tablet	Moderate to high	Swallowing convenience and pediatric positioning
Unit-dose liquid	Moderate	Reduced contamination and dosing error
New fixed-dose combination	High	Requires clinical, regulatory, and market justification
Long-acting formulation	Very high	Requires new pharmacology, clinical evidence, and delivery technology

A lactose-free tablet is commercially feasible but likely to face rapid generic replication. Its value would depend on procurement access, regional excipient preferences, patient segmentation, and manufacturing cost rather than durable patent exclusivity.

An improved oral solution has a stronger differentiation case because taste, preservative profile, dosing volume, and packaging can be combined into a product platform. The resulting patent estate could include composition, pH range, concentration, container-closure, and manufacturing claims.

How strong is the Baraclude patent estate?

The legacy Baraclude estate is weak as a barrier to ordinary U.S. generic entry because the reference product has already lost practical market exclusivity. A new product-specific estate could be stronger if it protects a clinically relevant formulation or a difficult-to-reproduce manufacturing process.

Relative patent strength by claim type

Claim type	Relative strength for a new entrant
Basic entecavir tablet	Low
Simple excipient substitution	Low
Defined pediatric liquid composition	Moderate
Preservative-free liquid with stability data	Moderate to strong
ODT with demonstrated performance	Moderate
Novel delivery system	Potentially strong, but high development cost
Manufacturing process with measurable quality advantage	Moderate
Method of treating chronic hepatitis B	Limited if broad prior art and existing clinical use apply

The strongest commercial approach is usually a combined estate: composition claims, process claims, packaging claims, and method-of-use claims tied to a specific patient population or administration benefit.

What geographic markets offer the best excipient opportunity?

The United States has established generic competition and strong price pressure. Commercial opportunity is therefore concentrated in differentiated products and supply-chain efficiency.

Europe and Japan have mature hepatitis B markets but impose country-specific pricing and reimbursement constraints. China and other Asian markets can offer larger patient populations, but local competition, procurement systems, and regulatory requirements can compress margins.

Excipient strategy must account for:

• Pharmacopoeial acceptance in the target jurisdiction.
• Local requirements for colorants and preservatives.
• Animal-derived or allergen-related excipient restrictions.
• Nitrosamine and elemental-impurity control.
• Availability of pharmaceutical-grade excipients.
• Climatic stability requirements.
• Packaging and dosing-device registration.
• Regional pediatric labeling expectations.

A globally commercializable product should minimize dependence on a single excipient supplier and avoid excipients with narrow regional acceptance unless the product is intentionally market-specific.

What manufacturing and intellectual-property barriers matter most?

The principal manufacturing barrier is low-dose content uniformity. The principal formulation barrier is maintaining stability and palatability in the oral liquid. The principal intellectual-property barrier is demonstrating that a differentiated product does not infringe surviving formulation, process, or method-of-use claims.

Manufacturers should prioritize:

1. Controlled premixing or ordered blending of entecavir.
2. Segregation testing during transfer and compression.
3. Robust lubrication control.
4. Comparative dissolution across multiple media.
5. Humidity and temperature stability.
6. Container-closure compatibility for liquids.
7. Microbial preservation or preservative-free control strategy.
8. Accurate dosing-device performance.
9. Supplier qualification for all critical excipients.
10. Patent clearance before commercial-scale investment.

How does Baraclude compare with other chronic hepatitis B products?

Baraclude competes clinically with tenofovir disoproxil fumarate and tenofovir alafenamide, as well as generic entecavir. The competitive decision is driven by antiviral efficacy, resistance profile, renal and bone considerations, patient history, guideline positioning, reimbursement, and price.

From an excipient perspective, entecavir has a relatively straightforward oral-solid platform. The commercial differentiation opportunity is therefore narrower than for products with complex delivery systems. Its advantages for generic manufacturers are low formulation complexity and an established oral solution precedent. Its disadvantages are mature competition, limited pricing power, and the absence of a biologic-style barrier to substitution.

Key Takeaways

• Baraclude is entecavir, marketed as 0.5 mg and 1 mg film-coated tablets and a 0.05 mg/mL oral solution.
• The tablet excipient system is conventional: lactose, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and standard coating materials.
• The oral solution uses maltitol, citrate buffer, parabens, sucralose, and orange flavor.
• Generic tablet entry is established; biosimilar risk does not apply.
• The best excipient opportunities are pediatric liquids, preservative-reduced formulations, lactose-free tablets, ODTs, dispersible granules, and unit-dose packaging.
• The main technical risk is low-dose content uniformity in tablets.
• The main liquid-product risks are taste, microbial control, preservative exposure, stability, and dosing accuracy.
• A durable new patent estate would require demonstrated technical advantages, not routine excipient substitution.
• The commercial case favors differentiated pediatric and adherence products over another undifferentiated immediate-release tablet.

FAQs

Can lactose be removed from a generic entecavir tablet?

Yes. A lactose-free formulation can use alternatives such as mannitol, dibasic calcium phosphate, microcrystalline cellulose, or co-processed excipients, subject to formulation development and bioequivalence requirements.

Is a preservative-free entecavir oral solution commercially viable?

Potentially. It would require an appropriate container-closure system, validated microbial control, in-use stability, and a formulation that remains chemically stable throughout the labeled use period.

Could entecavir be developed as an orally disintegrating tablet?

Yes. An ODT could target pediatric patients, older adults, or patients with swallowing difficulty. The principal development issues are taste masking, mechanical strength, rapid disintegration, moisture protection, and bioequivalence.

Are excipient changes enough to avoid Baraclude patents?

Not necessarily. A formulation must be evaluated against active Orange Book patents, any relevant formulation or process patents, and method-of-use claims. A minor excipient substitution does not automatically eliminate infringement risk.

Which entecavir product has the strongest commercial differentiation potential?

An improved pediatric oral product has the clearest differentiation path because it can combine taste, dosing accuracy, preservative strategy, concentration, and packaging claims. A conventional tablet has lower development risk but substantially greater price competition.

References

1. U.S. Food and Drug Administration. (2024). Baraclude (entecavir) prescribing information. Bristol-Myers Squibb Company.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. Bristol-Myers Squibb Company. (2015). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
5. European Medicines Agency. (2024). Entecavir product information.